Smoking cessation: An economic analysis and review of varenicline

Research output: Contribution to journalReview article

2 Citations (Scopus)

Abstract

Despite efforts to decrease tobacco use, smoking continues to be a leading cause of preventable morbidity and premature death. The associated economic burden is substantial, both in the form of direct costs (healthcare expenditures) and indirect costs (lost productivity), regardless of whether the burden is assessed from the standpoint of an employer, a health plan, or society as a whole. Cessation programs are considered among the most cost-effective in healthcare, and are often used as a benchmark for other medical interventions. This analysis specifically considers the cost-effectiveness of varenicline, a novel α4β2 partial agonist used for smoking cessation, in comparison to other approved therapies. Clinical trial data have demonstrated that varenicline has the ability to decrease cravings and withdrawal symptoms, and lessen positive reinforcement associated with smoking. Varenicline's novel mechanism has translated into superior efficacy in comparison to other available therapies. For this reason, despite an initial cost that typically exceeds that of other medications, varenicline is a costeffective option for smoking cessation.

Original languageEnglish
Pages (from-to)25-34
Number of pages10
JournalClinicoEconomics and Outcomes Research
Volume1
Issue number1
StatePublished - 2009

Fingerprint

Smoking Cessation
Economics
Costs and Cost Analysis
Smoking
Benchmarking
Substance Withdrawal Syndrome
Premature Mortality
Aptitude
Tobacco Use
Health Expenditures
Health Care Costs
Cost-Benefit Analysis
Clinical Trials
Morbidity
Delivery of Health Care
Efficiency
Varenicline
Economic analysis
Smoking cessation
Burden

All Science Journal Classification (ASJC) codes

  • Economics, Econometrics and Finance (miscellaneous)
  • Health Policy

Cite this

Smoking cessation : An economic analysis and review of varenicline. / Faulkner, Michele A.

In: ClinicoEconomics and Outcomes Research, Vol. 1, No. 1, 2009, p. 25-34.

Research output: Contribution to journalReview article

@article{c4ad8f970c704b098771b58f57fed9cf,
title = "Smoking cessation: An economic analysis and review of varenicline",
abstract = "Despite efforts to decrease tobacco use, smoking continues to be a leading cause of preventable morbidity and premature death. The associated economic burden is substantial, both in the form of direct costs (healthcare expenditures) and indirect costs (lost productivity), regardless of whether the burden is assessed from the standpoint of an employer, a health plan, or society as a whole. Cessation programs are considered among the most cost-effective in healthcare, and are often used as a benchmark for other medical interventions. This analysis specifically considers the cost-effectiveness of varenicline, a novel α4β2 partial agonist used for smoking cessation, in comparison to other approved therapies. Clinical trial data have demonstrated that varenicline has the ability to decrease cravings and withdrawal symptoms, and lessen positive reinforcement associated with smoking. Varenicline's novel mechanism has translated into superior efficacy in comparison to other available therapies. For this reason, despite an initial cost that typically exceeds that of other medications, varenicline is a costeffective option for smoking cessation.",
author = "Faulkner, {Michele A.}",
year = "2009",
language = "English",
volume = "1",
pages = "25--34",
journal = "ClinicoEconomics and Outcomes Research",
issn = "1178-6981",
publisher = "Dove Medical Press Limited",
number = "1",

}

TY - JOUR

T1 - Smoking cessation

T2 - An economic analysis and review of varenicline

AU - Faulkner, Michele A.

PY - 2009

Y1 - 2009

N2 - Despite efforts to decrease tobacco use, smoking continues to be a leading cause of preventable morbidity and premature death. The associated economic burden is substantial, both in the form of direct costs (healthcare expenditures) and indirect costs (lost productivity), regardless of whether the burden is assessed from the standpoint of an employer, a health plan, or society as a whole. Cessation programs are considered among the most cost-effective in healthcare, and are often used as a benchmark for other medical interventions. This analysis specifically considers the cost-effectiveness of varenicline, a novel α4β2 partial agonist used for smoking cessation, in comparison to other approved therapies. Clinical trial data have demonstrated that varenicline has the ability to decrease cravings and withdrawal symptoms, and lessen positive reinforcement associated with smoking. Varenicline's novel mechanism has translated into superior efficacy in comparison to other available therapies. For this reason, despite an initial cost that typically exceeds that of other medications, varenicline is a costeffective option for smoking cessation.

AB - Despite efforts to decrease tobacco use, smoking continues to be a leading cause of preventable morbidity and premature death. The associated economic burden is substantial, both in the form of direct costs (healthcare expenditures) and indirect costs (lost productivity), regardless of whether the burden is assessed from the standpoint of an employer, a health plan, or society as a whole. Cessation programs are considered among the most cost-effective in healthcare, and are often used as a benchmark for other medical interventions. This analysis specifically considers the cost-effectiveness of varenicline, a novel α4β2 partial agonist used for smoking cessation, in comparison to other approved therapies. Clinical trial data have demonstrated that varenicline has the ability to decrease cravings and withdrawal symptoms, and lessen positive reinforcement associated with smoking. Varenicline's novel mechanism has translated into superior efficacy in comparison to other available therapies. For this reason, despite an initial cost that typically exceeds that of other medications, varenicline is a costeffective option for smoking cessation.

UR - http://www.scopus.com/inward/record.url?scp=76949096140&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=76949096140&partnerID=8YFLogxK

M3 - Review article

AN - SCOPUS:76949096140

VL - 1

SP - 25

EP - 34

JO - ClinicoEconomics and Outcomes Research

JF - ClinicoEconomics and Outcomes Research

SN - 1178-6981

IS - 1

ER -